Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR)

9 novembre 2021 aggiornato da: Anders Fink-Jensen, MD, DMSci, Psychiatric Centre Rigshospitalet

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Randomized Controlled Trial (CRAVR)

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence.

Panoramica dello studio

Descrizione dettagliata

Recruitment of participants:

102 patients will be recruited from the Novaví outpatient clinics, where they will be informed orally and in writing about the research project and, if they are interested, an information meeting is booked. If patients show symptoms of abstinence, these are treated prior to the information meeting by doctors and nurses in Novaví. If the patient then wishes to participate and meets the inclusion criteria, informed consent is obtained and screening is performed using the questionnaires described later. Included patients will then be randomized to either:

  1. Virtual reality-assisted cognitive behavioral therapy (VR-CBT)
  2. Cognitive behavioral therapy (CBT) without VR (control group)

Screening:

At the screening sessions, patients' medical history is obtained, as well as their alcohol intake over the past 30 days recorded via Timeline Follow-Back (TLFB). Patients are also asked about previous alcohol dependence treatment and general information about psychosocial factors incl. education, work, marital status, and functional level using Global Assessment of functioning (GAF). In addition, alcohol-related problems are assessed using the Alcohol Users Identification Test (AUDIT), abstinence using the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar), intake of other drugs using the Drug User Identification Test (DUDIT), and alcohol craving using the Penn Alcohol Craving Scale (PACS). The Becks questionnaires, Depression Inventory 2 (BDI-II) and Beck's Anxiety Inventory (BAI), are included to assess the degree of anxiety and depression, and in addition, tests of mental function are performed using the Screening for Cognitive Impairment in Psychiatry (SCIP).

Intervention:

Included participants will in collaboration with their therapist schedule a standard course of treatment based on national guidelines from health authorities. After inclusion, participants are randomized to either:

  1. 14 sessions of VR-CBT (Group A)
  2. 14 sessions of CBT without VR (Group B, control group)

The participants in group A are exposed to VR-simulated high-risk situations filmed in a restaurant, a pub, at home, at a party or at the supermarket, to trigger alcohol cravings and other high-risk induced reactions of which the participants are subsequently trained to handle by trained therapists using CBT-based techniques.

The participants in group B receive the same treatment without VR exposure. The will be 4 weeks of weekly-biweekly treatment, followed by 20-21 weeks of treatment every 2-3 weeks, which is in line with the standard treatment in the Novaví outpatient clinics. The intervention deviates from standard treatment, as none of the participants receive pharmaceutical alcohol treatment during the treatment period (6 months) except for abstinence treatment if needed.

Randomization and blinding:

After screening a patient (ensuring that all inclusion criteria and no exclusion criteria are met) the patient is included. Participants are randomly allocated to either VR-CBT og CBT, 51 participants in each group. Randomization takes place in REDCap, which is a secure web application for building and managing surveys and databases. Age, sex and alcohol consumption are stratified at the time of inclusion ('heavy drinking days' and alcohol consumption - evaluated by TLFB). The technical setup of the randomization tool is performed in close collaboration with an expert in statistics, which ensures correct functionality before starting the experiment. After randomization, the therapist ensures that the participant receives the correct treatment and performs the alcohol craving assessment during each VR-CBT session unblinded using visual analog score (VAS). The study staff conducting the remaining data collections and the entire data analysis remain blinded until the database is opened at the end of the study. In situations where it is necessary to break the blind, it is possible to change the user rights in REDCap and gain access to the randomization tools. With the randomization tools, it is possible to detect the treatment (VR-CBT or CBT) based on study ID and all activities performed in REDCap are registered in the program.

Follow-up:

Each participant must attend a follow-up visit 3, 6, and 12 months from inclusion, where data collection will take place using the before mentioned questionnaires. The follow-up visit will be approx. 1 hour.

Statistical analysis:

All statistical analyzes are performed using the intention-to-treat principle, where all patients who have become randomized and has received a minimum of 1 session of VR-CBT (group A) or CBT without VR (group B), is included in the analysis. Missing data are implemented through the multiple imputation method and the analyzes are performed in the program "R" with alpha = 0.05 and 2-sided test. All continuous effect measures are analyzed using ANOVA from baseline to most recent measurement, and categorical data are analyzed using chi2 analysis. All data distributions will be assessed for normality by visual inspection of histogram and by Q-Q plots. If data is not normally distributed, log transformation is performed, and if this is not successful, non-parametric testing is used.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

102

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Frederiksberg
      • Copenhagen, Frederiksberg, Danimarca, 2000
        • Reclutamento
        • Novavi ambulatorierne
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO & Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

Exclusion Criteria:

  • Other active substance use defined by DUDIT score> 6 (for men)> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Terapia cognitivo comportamentale (CBT)
La CBT è costituita dai seguenti elementi: i) riconoscimento (ii) evitare e (iii) superare il desiderio di bere in situazioni ad alto rischio con l'obiettivo di prevenire le ricadute.
The active comparator receives 14 conventional cognitive behavioral therapy sessions with
Sperimentale: Virtual Reality Cognitive Behavioral Therapy (VRCBT)
The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Reduction in total alcohol consumption
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Percent change in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.
Baseline, 6 months, 9 months, 12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in heavy drinking days
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Based on the past 30 days of alcohol consumption using time line follow-back (TLFB), heavy drinking days are evaluated. 1 heavy drinking day consists of alcohol consumption exceeding 60/48 grams for men and women respectively.
Baseline, 6 months, 9 months, 12 months
Change in Alcohol Users Identification Test (AUDIT) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Screening for excessive drinking. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Drug User Identification Test (DUDIT) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Identification of individuals with drug-related problems. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Penn Alcohol Craving Scale (PACS) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Assessing alcohol craving. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Screening for Cognitive Impairment in Psychiatry (SCIP) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
The 20 minute test is a scale developed for screening cognitive deficits. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Change in Global Assessment of functioning (GAF) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
GAF measures to what degree a person's symptoms affect their daily functioning on a scale of 0 to 100. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Becks Anxiety Inventory (BAI) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Measures the severity of anxiety. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Becks Depression Inventory 2 (BDI-II) score
Lasso di tempo: Baseline, 6 months, 9 months, 12 months
Measures the severity of depression. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Simulator Sickness Questionnaire (SSQ)
Lasso di tempo: Each of the 14 treatment sessions over 6 months
Measures whether participants experience symptoms of simulator sickness while in Virtual Reality. Higher score = worse outcome
Each of the 14 treatment sessions over 6 months
VR-induced craving on a visual analog scale (VAS)
Lasso di tempo: Each of the 14 treatment sessions over 6 months
For each of the 6 VR-scenes, craving is evaluated before, during and after exposure as well as at the end of the therapy session
Each of the 14 treatment sessions over 6 months
Alcohol withdrawal symptoms
Lasso di tempo: Evaluated at inclusion
Alcohol withdrawal symptoms are evaluated at inclusion. Higher score = worse outcome
Evaluated at inclusion
Qualitative assessment
Lasso di tempo: After completion of a full treatment period of 6 months
15 patients and 5 therapists will be asked about advantages and disadvantages of using virtual reality
After completion of a full treatment period of 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 ottobre 2021

Completamento primario (Anticipato)

1 marzo 2024

Completamento dello studio (Anticipato)

1 marzo 2024

Date di iscrizione allo studio

Primo inviato

27 luglio 2021

Primo inviato che soddisfa i criteri di controllo qualità

10 settembre 2021

Primo Inserito (Effettivo)

13 settembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2021

Ultimo verificato

1 novembre 2021

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Virtual Reality Cognitive Behavioral Therapy (CRAVR)

Sottoscrivi